Oasis 500

Oasis 500 has spent more than a decade as Jordan’s most institutionalized launchpad for first-time tech founders, and its role for healthcare entrepreneurs is best understood in that context: it is an accelerator first, a capital provider second. Checks generally sit below $250k and are paired with a structured curriculum, mentor matching, and access to a regional alumni network that stretches across the Levant and the broader MENA market. The fund has historically been sector-agnostic, but its recent stated interest in digital health and healthcare software reflects the pull of MENA’s broader healthtech moment, where Saudi Vision 2030, Egyptian e-pharmacy growth, and UAE clinical digitization have all created tailwinds that splash back into Amman. For founders, this is the right door if you are pre-revenue or barely post-revenue, are based in Jordan or the Levant, and need first-institutional capital plus operational scaffolding rather than a co-lead at a priced round. It is the wrong door if you already have a Series A-ready metric stack, if your business is regulated medical device or therapeutics work that needs deep technical diligence, or if you are looking for a thesis-driven healthcare partner who can opine on clinical workflow design. The right intro path is through their open application cycles for the accelerator program, but warm referrals from Oasis 500 alumni or Jordanian ecosystem players such as Endeavor Jordan, ISSF, or Beyond Capital materially shorten the path. Cold inbound through the website is read but rarely advances without a prior signal. In a pitch, lead with the founding team’s domain credibility, a crisp problem statement tied to a specific MENA payer, provider, or pharmacy pain point, and an honest read on where Jordan’s regulatory environment helps or hurts. Show that you have thought about expansion into Saudi Arabia, the UAE, or Egypt, since Jordan alone is rarely a sufficient market for healthcare scale, and explain why your founding team can navigate those regulatory regimes without a senior local partner you do not yet have. Avoid leaning on AI as a feature claim without a defensible data moat; Oasis 500’s diligence team has seen many wrappers and is increasingly skeptical. Be candid about cap table: the program takes equity, and follow-on syndication depends on the fund’s strategic posture in any given year, so stress-test how dilutive the round will be by the time you raise a real seed. The principal caveat is that Oasis 500 is not a healthcare specialist. Founders who need a partner with clinical advisory bench depth, payer relationships, or HIPAA-grade compliance support will find this fund helpful as a launchpad but should plan to add a healthcare-native angel or syndicate alongside the program. Treated correctly, the value here is sequencing: Oasis 500 gets you to a credible first round, builds your MENA narrative, and hands you off to regional seed investors. Treated incorrectly, founders use the program as a substitute for the deeper capital partner they actually need, and stall.